雷珠单抗治疗新生血管性老年性黄斑变性的药物基因学研究进展

Research advance on pharmacogenomics of ranibizumab in the treatment of age-related macular degeneration

老年性黄斑变性是我国老年人致盲的重要眼病之一,雷珠单抗作为一线用药用于新生血管性老年性黄斑变性的临床治疗。然而患者对雷珠单抗的治疗应答具有个体差异,有约10%患者治疗无效。抗血管内皮生长因子(VEGF)药物疗效受多因素影响,其中药物基因多态性可能是导致治疗失败的重要因素。本文综述雷珠单抗药物基因学的相关研究,期待能为老年性黄斑变性的个体化诊疗提供依据。

Age-related macular degeneration is one of eye diseases that may cause blindness in the elderly in China.Ranibizumab is recommended as the first-line treatment for neovascular age-related macular degeneration.However,there are individual differences in the clinical efficacy,and almost ten percent of the patients are sufferring from ineffectiveness.Anti-vascular endothelial growth factor(VEGF)drug effects are affected by multiple factors,and drug gene polymorphism may be an important factor leading to treatment failure.This paper reviews the researches of ranibizumab pharmacogenomics,expecting to provide evidences to support the individualized treatment of age-related macular degeneration.